Abstracts

252 – Single-Cell Multiomics Reveals Systemic Immune Aging Acceleration in People Living With HIV

Background Chronic HIV infection is associated with immune dysfunction and premature aging, but the cellular and molecular mechanisms remain incompletely defined. We hypothesized that HIV accelerates immune aging through alterations in immune cell composition, function, and molecular signatures despite antiretroviral therapy (ART). Methods We studied people living with HIV (PLHIV, n=290) from the 2000HIV cohort…

822 – Dolutegravir Impedes Cerebral Organoid Maturation

Background The numbers of children born to mothers living with HIV-1 are on the rise. While antiretroviral drugs (ARVs) prevent mother-to-fetus HIV-1 transmission, risks of adverse events on fetal neurodevelopment associated with in utero ARV exposure remain. HIV-1-exposed uninfected (HEU) children exposed in utero to ARVs are known to have poor neurodevelopment across multiple domains including…

564 – Does 4-Class Resistance Affect Low-Level Viremia? A Multicohort Matched Analysis

Background Persistent low-level viremia (LLV; 50-199 copies/mL) is generally considered to confer a modest risk of virological failure (VF; ≥200 copies/mL). Yet, data on LLV in people with HIV (PWH) with multidrug-resistant viruses, particularly those with four-class drug resistance (4DR), remains limited. We therefore aimed to compare the risk of LLV between 4DR- and non-4DR-PWH.…

288 – GRAdHIVNE1: A Gorilla Adenoviral HIV Vaccine Encoding Highly Networked CD8+ T-Cell Epitopes

Background Adenoviral vectors have long been utilized in HIV vaccine development to elicit CD8+ T cell responses. However, recent trials have been limited by pre-existing vector immunity, skewed immunodominance hierarchies, and the emergence of viral escape variants. To address these barriers, we developed GRAdHIVNE1, a replication-incompetent gorilla adenovirus serotype 32 (GRAd32) vector encoding a T…

1039 – Balancing STI Prevention and Antibiotic Use: Simulated Doxy-PEP Strategies in ImPrEP Study

Background Doxy-PEP is an effective strategy for STI prevention, with absent data from Latin America. ImPrEP (2018–2021) evaluated same-day oral PrEP delivery for MSM and TGW in Brazil, Mexico, and Peru. STI burden was high (31·7 cases per 100 person-years), with nearly one-third of participants accounting for all diagnoses. While doxy-PEP efficacy is established, its…

348 – Identification of the Cellular Transcription Factor KLF16 as a New HIV-1 Silencing Factor

Background Despite effective antiretroviral therapy, HIV-1 persistence in latent reservoirs of T-lymphoid and myeloid origins remains a major obstacle to a cure. The molecular mechanisms of HIV-1 latency are complex and multifactorial involving numerous blocks to viral gene expression, including transcriptional and epigenetic blocks. Deciphering the underlying mechanisms that drive HIV-1 into latency is critical…

632 – Plasma Exosomes From Individuals With HIV and Cancer Enhance Tumor Cell Proliferation and Migration

Background People living with HIV (PLWH) achieve near-normal life expectancy with combination antiretroviral therapy (cART); nonetheless, they exhibit a higher incidence of non-AIDS-defining cancers (NADCs) than the non-HIV-infected population. The mechanisms linking HIV infection to NADC development remain poorly understood. Exosomes have emerged as potential mediators of this HIV–cancer axis as both HIV-infected and tumor…

902 – HIV and STI Trends With Rising PrEP and Emerging Doxy-PEP Use Among MSM in Tokyo, 2017-2025

Background HIV pre-exposure prophylaxis (PrEP) and doxycycline post-exposure prophylaxis (Doxy-PEP) are increasingly adopted by gay and bisexual men worldwide, but real-world evidence on their population impact remains limited, particularly in settings with low HIV incidence and restricted programmatic support. Because Doxy-PEP does not prevent HIV, its use without PrEP is a concern. We analyzed a…

1099 – Leveraging the Electronic Medical Record to Improve Linkage to Comprehensive HIV Prevention Services

Background In the last decade, Arkansas has seen a substantial increase in HIV cases, yet utilization of HIV prevention services remains low. Arcare is a nonprofit primary care organization that provides comprehensive HIV prevention and treatment services, including behavioral and biomedical strategies throughout Arkansas. In 2024, Arcare conducted a review to identify missed opportunities for eligible…

376 – Candida-Responsive Cells Contain Intact HIV-1 DNA Despite Limited Clonality in Blood

Background The persistence of a stable reservoir of HIV-1 infected CD4⁺ T cells during antiretroviral therapy (ART) remains the central barrier to a cure. Antigen-driven proliferation of infected cells is a major driver of reservoir persistence, yet the role of repeated antigen stimulation from commensal microbes is poorly defined. Candida albicans (CA), a ubiquitous commensal…